Difference between revisions of "Hypercoagulable state (thrombophilia)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "*Surgery" to "*Surgery") |
Warner-admin (talk | contribs) m (Text replacement - "[[Paroxysmal nocturnal hemoglobinuria (PNH)" to "[[Paroxysmal_nocturnal_hemoglobinuria") |
||
| Line 14: | Line 14: | ||
==Acquired thrombophilias and clotting risk factors== | ==Acquired thrombophilias and clotting risk factors== | ||
| − | *[[Surgery]], foreign bodies such as venous catheters, smoking, obesity, elevated factor VIII, advanced age, male sex, trauma, sedentary state, immobilization, malignancy, myeloproliferative disorders--[[polycythemia vera | polycythemia vera (PV)]], [[Essential thrombocythemia | essential thrombocythemia (ET)]], [[Myelofibrosis | primary myelofibrosis (PMF)]], pregnancy, medications--e.g. [[Bevacizumab (Avastin)]], [[Lenalidomide (Revlimid)]], [[Thalidomide (Thalomid)]], [[Tamoxifen (Nolvadex)]], oral contraceptive use, [[heparin]]--in the case of heparin-induced thrombocytopenia/thrombosis (HIT), congestive heart failure, anatomic/low cardiovascular flow states--e.g. inferior vena cava (IVC) abnormalities, chronic inflammation, inflammatory bowel disease, nephrotic syndrome, [[ | + | *[[Surgery]], foreign bodies such as venous catheters, smoking, obesity, elevated factor VIII, advanced age, male sex, trauma, sedentary state, immobilization, malignancy, myeloproliferative disorders--[[polycythemia vera | polycythemia vera (PV)]], [[Essential thrombocythemia | essential thrombocythemia (ET)]], [[Myelofibrosis | primary myelofibrosis (PMF)]], pregnancy, medications--e.g. [[Bevacizumab (Avastin)]], [[Lenalidomide (Revlimid)]], [[Thalidomide (Thalomid)]], [[Tamoxifen (Nolvadex)]], oral contraceptive use, [[heparin]]--in the case of heparin-induced thrombocytopenia/thrombosis (HIT), congestive heart failure, anatomic/low cardiovascular flow states--e.g. inferior vena cava (IVC) abnormalities, chronic inflammation, inflammatory bowel disease, nephrotic syndrome, [[Paroxysmal_nocturnal_hemoglobinuria | paroxysmal noctural hemoglobinuria (PNH)]] |
*Prior venous thromboembolism (VTE) | *Prior venous thromboembolism (VTE) | ||
*Antiphospholipid antibody syndrome (APS) | *Antiphospholipid antibody syndrome (APS) | ||
Revision as of 18:42, 31 July 2019
Inherited thrombophilias
- Prothrombin gene mutation (G20210A)
- Factor V Leiden mutation
- Antithrombin III deficiency
- Protein C deficiency
- Protein S deficiency
- Dysfibrinogenemia
Controversial:
- Plasminogen deficiency
- Factor XII deficiency
Acquired thrombophilias and clotting risk factors
- Surgery, foreign bodies such as venous catheters, smoking, obesity, elevated factor VIII, advanced age, male sex, trauma, sedentary state, immobilization, malignancy, myeloproliferative disorders-- polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), pregnancy, medications--e.g. Bevacizumab (Avastin), Lenalidomide (Revlimid), Thalidomide (Thalomid), Tamoxifen (Nolvadex), oral contraceptive use, heparin--in the case of heparin-induced thrombocytopenia/thrombosis (HIT), congestive heart failure, anatomic/low cardiovascular flow states--e.g. inferior vena cava (IVC) abnormalities, chronic inflammation, inflammatory bowel disease, nephrotic syndrome, paroxysmal noctural hemoglobinuria (PNH)
- Prior venous thromboembolism (VTE)
- Antiphospholipid antibody syndrome (APS)
- Lupus anticoagulant: dilute Russell viper venom time (dRVVT), dilute activated partial thromboplastin time (dAPTT), Staclot LA (hexagonal phase phospholipids), Kaolin clotting time (KCT)
- Anticardiolipin (aCL) antibody IgG, IgM, IgA
- Beta 2 glycoprotein 1 (B2GP1) IgG, IgM, IgA
- Sapporo criteria for APS